dr. tew evaluates bevacizumab treatment in ovarian cancer
Published 13 years ago • 1.6K plays • Length 1:36Download video MP4
Download video MP3
Similar videos
-
1:05
dr. essel discusses long-term bevacizumab in ovarian cancer
-
1:06
dr. jason konner discusses bevacizumab in ovarian cancer
-
8:15
bevacizumab in ovarian cancer
-
1:40
dr. hardesty on bevacizumab/parp inhibitor combination in ovarian cancer
-
2:19
dr. arend on fda approval of frontline bevacizumab in ovarian cancer
-
1:19
dr. essel discusses adverse events of bevacizumab in ovarian cancer
-
4:54
bevacizumab in recurrent ovarian cancer
-
3:42
parp maintenance bevacizumab in ovarian cancer
-
1:45
dr. liu on the use of bevacizumab in newly diagnosed advanced ovarian cancer
-
5:41
bevacizumab’s role in recurrent ovarian cancer
-
6:57
bevacizumab in platinum-resistant ovarian cancer
-
1:12
dr. herzog on the optimal use of bevacizumab in patients with ovarian cancer
-
1:40
dr. burger on the toxicity profile of bevacizumab in ovarian cancer
-
8:03
bevacizumab in platinum-sensitive ovarian cancer
-
3:13
dr. herzog on the fda approval of olaparib/bevacizumab as frontline maintenance in ovarian cancer
-
6:04
when to add bevacizumab for recurrent ovarian cancer
-
7:24
ovarian cancer: maintenance following frontline bevacizumab
-
2:18
dr. mirza on efficacy of niraparib/bevacizumab combo in recurrent ovarian cancer
-
2:56
patient selection for bevacizumab in ovarian cancer